HUE032539T2 - Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására - Google Patents

Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására Download PDF

Info

Publication number
HUE032539T2
HUE032539T2 HUE13704171A HUE13704171A HUE032539T2 HU E032539 T2 HUE032539 T2 HU E032539T2 HU E13704171 A HUE13704171 A HU E13704171A HU E13704171 A HUE13704171 A HU E13704171A HU E032539 T2 HUE032539 T2 HU E032539T2
Authority
HU
Hungary
Prior art keywords
hogy hogy
ija
antigen
hbsag
vald
Prior art date
Application number
HUE13704171A
Other languages
English (en)
Inventor
Landry Bertaux
Isabelle Chacornac
Alain Françon
Jean-François Hau
Graf Sandrine Lentsch
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of HUE032539T2 publication Critical patent/HUE032539T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/00034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Description

ObÉÜii&s&fs
Ittekvesikm rsfstsrW toli Si «aleae© thmsisdhf'# Ü* htfpiát i ik\Bs&amp;^mé*yMömi%>h!lm tyiumgmtyp® b vaienvs. ttmd&amp;dttg of its <s«j>sal8r:^i^m«Wd«, called piMytiixisylsMöi^hm^te^R?), whifcb iapi« má&amp;r U> he eifceUw w children t»tdér eoigagated mmmísf fawtein* fbrexmspk the tmimíjfre^is&amp;í·· :&amp;bh samfekstjosss ^ífekpssMi^sá^ls'^iminiaimfclfe ynnag ^Mt^.gei^^^í.ew^ÉgíiS^K^.sa^tg^ís: that «ifi :i:pi?ssi&amp;k dó:ysesstsaíd spfest s&amp;vsmi diseases its a skgfe oixsaSion,. ssiá stísss as aitimbmimbssss! adjuvant. iíafest apphítatkísis WO öabfObM5? sxmcems ihe pí<?l>iem oí vsomrc stsMIÍty ami teeomrooíKlst wh«a the hepatitis B arttfps is |MW%. «wtál^^^feg-tí öto stifcimlsmm byimside; &amp; is reeofmsemfei! is a<fesri H mm iiktmimmM0imyphm^mk or tust k· sdkssb b<
Pmmú appiiestot WO bWíSBCib cilsckíses a vaeeme eompossüon eoinpmmg, as k dssmhtd ott page O, antigens sifepisg líspstlls:© atsd ·%&amp;βι»ψΜίΜ -i0mmm type b te 1^ sáyoilssásRfe ss sltsmtotn salt is srder P> &amp; immsmogsiáis 'fhis is m: patt kkarifte ew:«itfe"8te Itepatkk É snrtfee anipn nrMSs Ag. ÜöWever, ss. is indicated sxi page 1?. of application \!!i$ö 9WK19Ö6, theiöih váláséit.. consisting ísiiiKe t^pssíiáF .pi^saccharklí txmjngated to ?he fctatsus proton, has a fandeaey tn io« its intmranogeaistty over time seben «is aliboBkíd onto almntnutn salts. 1« order to avoid thss drawback, the solution proposedtutilig prior art p asistd stsstady beets tecomtstended is the prior applies boti K'lVFRyet-'OÖ79I, to add anions aodiioípaftístdiaí ydsophaíe,; «ssbösale «a'ieltfsíe isssi: ítevvcr, tbc athbor» sí the present inveftiibrBin^toed üks!* khifedői»· addition of nms* iniprtiaolar oi: :phssphdtgs:pteersa?to?yiiísf atnsaiiy mak«&amp;i|:pössMfetö ps^vesttítheisílissppíiíts of tW-'í onto atomimat:! oKltSd hjnh oxide tAHHJHt. and sheredtrrdb .; maintain ii'1»«hrtí||^My'Stíy#atm«. this addhs^sÍj^vfe»S';''ÍÍ: terhsek of desorbmg the hepadris B sutllee autfgsst syhsn itbe MerflMt. fc<*lf. also hepp nisoihtd m®. atasÉhdn oxide hydros ide ftklkereíbrc necessary ts üsd a method tor preparing a vaccine coobbsiaiam csmspmhig nímiuatrm xixlin hedroaak so wlneh tt\ tiocxn v* R sbiHu e .-unpoo >*> kor 5 nhmtxd 0¾ xkiOH. ohxie.'S:dmBti> songén tg Isspí: ssmiKigmbed. Ίο this end, the subject <>i the presotsfíftsvaáitm: Is s:isethod for preparing a Snpttd vasc-ka esmbibsstlsn .Vv'tüptts'ngai least • ooebepatltss 0swtface^.stspesstUBsApi -.,· «»- ......—ππ:·ι·-·ιιΤΒ'ΐ8ΐ' - one /íi/Swwroe Svíx·. h (Bib) antikon eonsktiog of capsular poiysaecharsde XAnXgsted nt a cntrier protein. - aiunnmms oxide hydroxide (AiOOSii, la which tbc hepatitis B sártök anhgers te k«^t ΡΘ£Η| .$§: i$ ffitpf nonadsorbeds wherein: - the hepatitis B sorfa*. a antigén k adsorbed onto ÁH iOt t aj order to obtain ao AlDOH/HBsAg ίΧοοηΙον, ::» sasd AiOOiidlBsAg complex is mixed wish the Btb antigen in the presence of caskmtc otnirto add» «1 a vo>\'«»th»iO - <.H &amp;s teást töd ,ng I aad or phospoak κ n. .a a concentration of' s^ >H mMoi i
By 'íátoe of the method according to the invention, n k po-jdbie m achieve he desired balance ix iwe*. n looping the aasotption of the hopatUix it surface antigen on sire ahntsintsm aside hydroxide anti keeping the ixmmiiOr-pfh'O of the ihh <mm\o
According to one particular innhodhneas of the inventions the SiBxAg sohgars 1st adsorbed onto she akinlmiost bp nevnx ;'s 'itvrn.o ' r»f AKOB wxn ' s,ím esw »n of 1 B \g vor -nsta'g tot at icost 4 f»\ i' ptoterabh sttkwi 12 honeg preferably between 20 and 24 bonts,
According to one pamcuh» embodiment of she invetifiou the: etsijpslc asnlpp: stkidv are added.....to saM
AiiXIi'kXiBBAgcotnpicv before the mmag with the Hih antigen,
According to itt· aítentaítvecmhoái»^;iM^|w#^^^bfilc ssntösvtsdtdkWstktó topáid Bib antigen before She mixiog with the AKX>lbB§Ai|§ebtpgte
According to doe ftplmdiment of the ipphtiöö., ||^ phosphate Idas aid added ;Hfpi4ÉI^C^^Ág coipptek before the tnixing with the Bib antigen.
According to ppg dixtbrsdimem of site invention, the pH §f|^f:VgrP£>ipM^ sskhpioXhl the ÁlfhBfÉBSsAi complex k adjusted to 7.1 ·> (s. \ before the mixing with the Ihb antigen, lie subject of ihe: Ihvciihtn teteit ipcfPOTöbfesöMi id the snethod efahsted and conspri?;i:og at least - the· hepatitis B sortaco antigen» - the diphtheria antigen h the form s>f diphtheria toxin D, - she tetanus not igen in the fetid of tefastss tnkin T, ' die whooping coogi; antigens in the form of Pmifisd InsinfPfvd) and of Rksmentons Hemagghsttmts (FHAy - She Hwmopttilui Og/ocoroe type:h gntlgest> in pk«tphsík..«ö»iti^y-:-to the teMRos protein (Rif- 14> • the poiio antigens tit the form ot inscitvated type l, 2 amO vimses> terds íí: vatxdnP ípornghyjtsóh hte: thé stttiMli* öf Bájtig SS tlsslö: 1ss?sS: SsfefsSV: axdidmig Q|56;^Hös:ss: Is iíökö >%ψ xfhailyttpbtlisate. 8 has prove» to be teteietstly xtutsle to rem-iks immunogenie nodi bx·. buy sí iiw^iswii st> rrsstes after its date of msssaf&amp;cttire A««*^3Rg.--to f§&amp;'.vaeted pomflositioa comprise* a Ixepatitis 0 mííükí? assisges-s tsRSsAg). Ibis tetgds:r sssry ds prtetsjar be a hesteteB tette antigén ste as. tlw »8« present ws the Reoosuba»:·. HB** «vtódssá* teío assy pite hepatitis B teteé. b may is* partiadat be the reeombusaht: tesgnn entajoed by tteseisisstte xsf §. /termrte />ís/mi»fte! yeast which te tens nsxtesexl, a<-.«. s>í-.Hf v κ» she texbosungy teteoped by Crucall, ssseh as the ssrse preste in she Hepavax-Gesste voocte te stse purposes of the teteson, sSe .smooth of HBsAg present ás a 0.5 mi dxaasis sdvansoge-oasty stexveess a üshI i:> kg: abá is particular iö pg ,,Actor<h«g to she invention. the vaccine composition e:í>s«peB«ss S type fe iitib) antigén. 3 his antigen consists of ds« esspsste polysaccharide of she hae-terimo or lteysteo*y3Rit>iud Phospte* iRftR) umea s-< μ.'!''«'\ΡοΡ h« a smu< poneO 'he x.·«*ser psote srs oho S'e an* sutesr ,*sed os ttv- respsxt as te teem* flékl 3s tm> he, tor example. diphtheria toxin t>, isipMsis f, i.iaemophihss s^hemaa lipoprotein Ö, CRM 3 $7 ra she Λ?, meningitidis outer mombrane protein (OMVl Use *s preferably made of the ivtams* pi Site isi teles- tetette the PRR-T etette, fdf the ptesBgs MM® present invention, the PRP-T conjugate .:may be present in a proportion of from I to 30 gg of I-RR ptedJ ml dose; advteággteliy froth 5 so 2b up ol » per dose; preferably from 30 m 15 p§ ofPRP M.1»: dE>se} end more pamctdariy t a pg ot i'S ib conjugated to 22·· 3d gg.-oftote«s prs>s*sn.
Afeordlbg so she inventsos, ibe vaEC*n6 CE>mjH>5«i0S! cotnprsies alostsisusm oxide hydroxide ARK-Bi ihss idssptbssMfs Stv.< (s Eortmnís3s n«.<'nc%.»S* v^ilc-uab»' 'ixdts'Xtdc tu.v \RRds srbKis oats bo sisód kss-te fgis'posbb i-is'jsse pressnt inveinmn m&amp;\ be, idr example, the ΛΙΟΟΗ sail sxsRI by Brenntag AO, or R«hydrage3 |is \ i»os >·. h ivn (Uj^ies ><te' '·< Μ» eísK'ug** tb, >"i^ vd oi f \k tsxs' so v,sxh κί he two adjuvants diffets. l isa asnoant of AbdiH used is csüatlated so as to allow a satisfactory tsnmyne response us be ssehkrxad; ;s depends.:tn parsissular ess the nsnstbei assd snt she nature ot the sssssigetss ptesens in the tomposltldu end also on sins amount of eaelsiofthsms arttfaetw;· sb-sresy by \v;iv of suformanon, the oíSsíoíSos adsorption ot HBsAg onso Λ100Η is 3brass pg ot ps'oseas per sog of alnniiinssfs teorsviOititBi-idy. ihc arnysint of Atr.)OH ss expsessed as ararasiv; ot aluinininn AÍ s bof a v.;.'viS;> sb'···' í '''.ariis.a ' :st pe os'sss3'.s^ aba-^alae\ other sddit-ossei a-usp.esss, s ' pg os yjonuuent u<'sssd sees liSidVne ukius· a ,n> aniossns sSaP i: hesxvever isj4ufteii.'nt so «obtain the dessted ett'seaxy vvheo oshes' sasi gens are ssddeb. Thus, depersdiug oss she ssiktisiots of one or issrsos iutsSitisusat ansigxau. IÖ ng xs? HBsAg stay 3;e btoujdu stssx« aonts,; x« s«s« isxxssi 0 OS nsg So 3 mp xo siítanntotn "·χSo, Is o. OSx' ssao -usosn .sinosoa ',e,x>tranx teas by Shi itepfeatSi |íhsrts8és>te la s
For o\.mspk, « d,5 ob dose vt a gr 4' <ts r ^\s -e \ oevpi ssnrg diphibo as ses mm . OrfKOptm. o»ttí«ih ami mpaUOs B ; v ííís- mm m '.mioo' ath n óm s - ».' sí; y os am hí ο, p-o >. okik ayrm s‘sm.eh dt> rm: Ά aluminum.
According to the sttvontion, the hepatitis 0 «.urfctee antigen is kept a-terhed o« AKX>Fi, which means ihat at H:<ssí 60%, preferably at kast *5%, preferably as least ?U%, prefer&amp;hiy at least 7$%t |>tefcr&amp;bl>- at kast 50%, preferably at least %$%, preferably at kaas vo*·,», preferably at least 9$% of the total amount of this antigen preseat ie the composition is present so adsorbed fosat.
According to the invention, the Hlb asdigen is kept nonadsorhed s.>n AÍUOI1, which memo. that at least b5%, preferably at ices; 70%, preferably at least 75% of the total amoaot of this ant ige» present sís dm composition is : presentin nost&amp;dsorbodifhrrit;:
AuvOsJ-ap to she s os'so.o \ the period -Ί isme do* mg tv Inch hemmtss B sut'me osrí.v i is k>.pt s^otboo on she Ahkdt ,md tie 'tsh ontigut is kpt normAm he J se si leal 1 rc»x:h*. os e feral'v at kist A month , preferably ai least id nnmílm, prefemhk- at least 15 months, preferably at least .M month;,·, more preferably .0 •east 5b months start sop. fo>:o the dale of ιοηποίΧιοπ? of the composts ioo, o so··!', the storage- temperáimé ss 3 e 'X 1% „«abb lm Oil s sb'ski* is i ί e set Kd tt s>gei e ts B.be os O' S sue hm s s> o si ' ' *\ provided shat o remains onhin acceptable Homs i'kus, svhmi at least >555« of she tótat ásnom** of she IfRxAg present la the composition ο adsorbed on the AlUGH for 3 months starving from the elate of rmsmbiieture of she eomposikots stored at a temperature of 5 > 3Ό it is emirtdy possible that* after eme year arat still raider Pm xamv stoispeeshdiiiotis, 80% of she: total sipieioal: Of the HBsAgpfessm in the composition is kept adsorbed. io order to assess
Wish regard to tfeb siefsrrmissatkm ot sire percentage adsorption of the HBsAg. it is possible to use a swittakh 5 11\\ 'oeih'O ckomime s % ό d oied b·· ilv i οό'ν< « pixanaeope 1 3 ! A-χ-<1\ o, HA v> > ,φο,οΐΐ' 'Sin ÜHxAy p.i!-are O'Oses un,* ü i'u't O' LM >p, u weih o« « Am'I pan* loo HO-it s.s.' ssoiid ín <.oök'il with an ^oií-HBsAp seoesadar. monocli>o;-J aelibody, oilgG type, which is itselfdeierled by means of a peroJiidase-eonpierl artiklgt.» polyclonal antibody. A chromogeriK·: substrate lor peroxidase, íeirsaiedivlbosi/idiar t VMB), ^ives as a {Sevelopom egem. When st is added. &amp; color develops the tatensity of usooh i.i proportional so dm aoiomti of lIBsAe captured m the oeli the ivsoiis ore simlyaed accmsfing to she p(o.díel Iοic osotisocl elesi-nbod no tbc 1 uropean ptsasnmcopei&amp; Ihe pCKOougc adassrppon is öblhlPsd tan jise déteirsiiaalioíi of the tsrtaS HBsAg content mxiof the nooedsorlxal MBsAg content.
Wdh regard so she ammon of iK-soidsoBjed PdP- i the evalaaluxs can be earned out by ilPAl.-C-PAf1 (Ibgl*·· perfostsiaiiCe ion exchange chrorom-xgrophy - piilcsxl amperonk-irii. dettetion). x.,uiobog io ok-mcilonl vd tlx m\,ntiosi tk hepatitis ft i<mfmo anngeo ο. ,ηΧοΠνΒ onto bíOtílí Hns stop caB he carried oot by bringing the hepatitis B mMm aotigetríioíl iho AiGÖH inks contact to ibe abscsice of aoy „íher atóiprn ami allowing tóé hepatete B snsike nemem to tótónh mito tee AiüOH for o lenit 4 temt>, pipfembly s) Seató 13 hem's. entnoiy preiersbly betweee 20 ami 2.4 boom, m m< i&amp; okain a preparation i^mkmg m AléOM fiságeMgieió Ibisvafefpím «tói tó mrtM'-&amp;tá, -.seeing tó tóé tósotótók tó ;fe atóeace; of phosphide fees, -14¾ objective pmaeeó by mosna of»|5fö!«í3gí;d: eotóbeí ime betgen the hepatitis B suá&amp;«r:«tfifes -ától&amp;* : AfCTÖli grists:.·tó másMisiig d«íí«mtóffc Mmmíímm má tó : jtmmsf mg- #4 e laíetmtóos* wtótdt mn ihm rmiii tó wblíSBmsg,
Aseerdtegm ífe msíboitóf itó Invtóttóth tóé AMMWisAi Mipsat tó mised with ttó tílitsmftjftm 1» tós pnesesestófésífímiéami^iB acisfe: ásd or|tóosphafsJíss&amp;.: Föf tóé B«n>osestóf dtó ac«fc!i is. mtendetóio mm pHi is tógáé? tiuí« die giii of4lje-v»^te-eo^e«»tí«9»;^á'í3wfwch will therblfeee be sv ctóí<wtó IBssa et tóe pfiöí üie..v»ecine. these esc ile partteyí&amp;i Lyshte (Lysh Argmioe tArgt m idistiddis (His)· eseh örtóe^tóídhe iscids SiSfhtó-UM* n « i t nMm mt < lepi .ills ‘ Ve * i- He \ > |i\' ^<|. 'W*Vl? U'i * Vg íHis), Aecorbtóg tó s»te:pÉltófcmbtó|«»nB the eatksm·. smims ssids may be assobiitbd tó tósseptóeMm,· 'hlemtot*:«y :faÉfediaHy be rnsdb of die dipeptjdes tys-l.ys, :%s*Aíg. lys-Bis, Arg-Aíi, Idsd-lis.lltó-bysemf H»«At&amp; Alfemaite«4y; a dipepbde of i^elsrthe poroses of the presetó fnsetóitm stray tó *m$mé. alfa sísdohte «Imi asdb mtd of -est sísefsafietó^iesi seki sefetóed fftóv Áfa, ¥sf fka Jso. Pso, Me| Phe. Ίφ, Oly* dog Tht, Cys, ϊy>\ Asp aod xa»öf&amp;^::b:p^c%-»:|»^pmba:cMtó}i%;:«^*»ss»«-5aid^x ammo etid^s) in hoc amfor dtóeptide form may he esed. it % sf^i jmsslifg iomse stótóo setd timpomíiötss ;. isnps n '> o sn on, »iiJ » PtNoeriiam» « >*»» \ »te-wtáttmer:Mgfe;^^ifestó«^idptó*Re:: .too gr*a? a drop tó the pH dóriiig the addídsa efthe ammo acids,, i? tó possible is etiviskssi ímMsmg the pitóf the prepamtas eessipHsió|:4hesetd:tóo imíbtóbemre adtlsgiift tó Ató Aií>Of4d4B$Ág eompteig by msaes of a: base, ippt$i««fk:RidiömIliyiáro,Kklaí:.: Áeeoídsny to theloveotiöip: íheiemostóiAjfissttótae atóöo ittóds dlffssMdeiy pt^^f:.ötil.te;-:saoótego«tpas^öíV modi be iít teasí iCiif mgli*ptótóastggsousiy m fetói; lööisia^f,; iafcoiaf^^^váti&amp;así Λ mgl -m«é&amp; prefemldy at te-ast lett otg'h Them itittö'itófitói:masifeöm-i.dose,-.;Ö«wam^I:i:%pdlM6fe feritei-:«tax8fi«m .«tnornit to lx- at most 4 mgtóth more preferably at pmsl 1 .οιο*«:ρ?«Ι&amp;»%. af:-te'#!S' #00 jtgfmL eofbtdy pefembiy at snovt TOO ngdtd. \bhsm caiceiaaieg ihe aotoodt of ctómnlfe ámító acids toitó added, the oafteale iBbteo acids that >sm> be iaooiitKvd by the media it·· •^Wz:iWm\$’m:®Ém:· then SiBsAg áed tóé Hsb aot»gett nresceS a tend d in· mlu-o ode ^ocooati iAecotding lo a,ne sitemabm of-the 4«íÍife«»ÍKt-;fc-aws^d: #í tókmte reiative to the weight of she fiib-.eo|tó^ar4tóÍtel^3«.^-1«.iP«5fltteftó*11ih-:pi|p^«ia^iÉctó<tótó'tó?tó:
Otód vuvht f OiO ni ! 4 V 1 5«tó ο>Κη»ΐ<'<νοι«ιΚ of ϊ Bitot ftg pjeternbh ot 1 l>tot t,0. or peatn obi· te iprok-raidy of i. id isi I: Jo or 4ii<
According tfa Ihe method ofthe ktvsklbsg imAliKiBTtBKAg s^misls^ ila ^^^^wisSs t^Afib sndgertd&amp;Afes pmsmsi· Mmtikmfa tmtlito ««Ids, 'bt#sfe« fa sCpe^'»ta.:íi»»i AesmsAg te Qrs^sH&amp;mdímet» «£ Ι^ί^Α^ν^ίΑϊ^ϊΟί^.ΙΙ^^χρ^ΐίκρ^^ϊίί-.Ιίΐϊ^ϊ;: isr« :Jíiblg-b ;1:« tbb: A10ÖI ί>;|· 1 ϊί 1¾Atg: <ϊθΤ5ΐ|?1«5ί bieíbf« SÍ: ís |>^Kíg:h3?íίΐΐ wíííΐ :fc>lí!b 2jÉ%^jí:.:T^-:^tepto«4e!«s «a^rfe-b^npNí fee sss4fcw:ftssÍR»g«8. phosphÉe $r :píbsiam;l^áf!^|es phosphate, t«f ehmrrtMure öfife tw 'Wmmmmt of phosphate: tons is calndnlM so ihsi i8ie.:«wla5«myi8ísoam of hepatiks B swd&amp;og muigens reread ajilösrbud ok the AI£®| wfeiie at the Sasié lipid avíiding fe;atfeurpiion of the H?b tmigpn, 1¾¾ atwmnt vafiss; according to the auilgeos pr«^{%a«é'in particular atoetdidgipthoaoigoss otfeorthao the lIBsAg asitillífe sdtipös.
Thus, u>r.a':vamsvs oimihioaiios com|>mihg the aaiigens ppratalljr »É^1ó,p^^^-íKtóá^ ihat Is 1¾¾¾¾ id addition to. Hg IIIsAg and tiis W^nfegmjjEfee.^jiltiheria, tetany and whooping cough antigens, it titanic adyamageons to add phospbí8i'$É|K· -mfaiMgá tbt..phosphate km eo«eot#af|t>a Is the vacehie compfeslÖöft' íölimatehs obtained Is at leasi egoa! to 35 hthfoi/'k gob «wre particularly Is hetvveea 35 &amp;ικΙ4$ mM«1/l< hlhjis uncladed. ptvíeraidy betweea digltd 44 mtMbl/h IMIis kichided, srtitrdy preferably between 38 and 42 ttlMokL illMlis Included Wording to ood igrefeshk) eutfeodknem, the phosphate loo . ermomitcaison In the vseeidf family ojklrmed Is4d othfol/k
Apsordtng to ott .omniatn > "if-' '«htrem, «he px> phate mm an aided m-tm amount »uoh that tfrc\ ate p*e*e«!
Is the vaccine composition «t a tmal eonecaif&amp;tkm of jkdwssn 35 atsd 3S ksMPbk hokis included. This, ip «ipleted |>y uko adding «.athonote Ions, but in a limits M0MÍMMS&amp;Í idee it has in íaet lkam SpWdbid: an excessive amount of c&amp;thonate ions Is ufdavorabk. Advantageously, they may be added in an «.mount such ο η '\ \ m- present ϊ' te vaccine so* 4' "'>'i<n, ht> d <, veer’ruttoti ot loss than >« «-'gnai tu Hi m\kd i
In shock etdeh could destabilise the HBsAg and promote desinptum thereof, it
Is:tm*wtigt«feá lörftM$fe®:::$feö$ph*iu· ions η» several «exampk >n 2s dsstmet operai iim» tsteps). 1 feus, the phosphide kmsfsmtiy:lk added M st drst ooemtion,. I» a η.οιγ wl Jv ^tLis t p »' e to ae u \e a <nl mmmkfami of between 3$ timldO PtMoh. ΙοηΙκ Included; then, m a secood operaion, in an amount a huh makes ífpmsifelelQ-aeMfesfS^lrsáfewteieniiríttjeh 4 s specified dbbys:.
Acsordmg te- one, preferred emfeod invent «ft the- method according to the us yen; loo, the nB of the preparation oosa not s t 'do tn Jjusteu to 7 t + ! t Hostgtm Mn nogs « λ rh th« '5k4'tBBI"\> « > pies It has In fact been noted «hat such a pl I vine das a positive effect on keeping the Bin antigen in the nonadsorhed state. áecocdiítgto omipmu-'olar embodiment, the >>! i Is in addh Inn adjusted to ” I ± 0 Í a*et «he mo. ng ph^ce llnSj l%- vtttye of the meahod according to the invention, it k possibte to ofetalt» a HKome v»v;nposkioa in svhteh: - t (I; feast 60% <>r §0%. preferably as least total áSMstmf of (he-:i^iis:fö-:spte^«sii^ pi'CSOSt; fit Síi? vOOspOÍJhOSi H Uihorhfcd OSt Üfe AtfOfiHfeír Pf feSisi O SS!S®!S StSítíítg ÉtSift: Íli8 áate oí StOOiohí-Oni. <d Ú!é eOOspO'öSiO!! SÍOi vd .>S -.; tOüSpeoidiK' OÍ -'' i. 2Ά S -hid :||1| as jtefesí d$% ?ö% a- 711¾ %i:táiát:::8»tötó· ö$ Öfe'Hib·· hsoörn enmpöátfp ia nai sdsorhess os sin; A ti K dl tfe expresssoíí -‘AlOOt l/t l*UAg e o*tó<*·4 shöhlífbe sníeq:5Föíí3íÍI tiS intessí5tlí5¾¾ ífeö «|>íe?s s*s aifétó
Isti HBsAg antigén adsorbed on AKXJM. The antlgm^sitál^ ÜaÜ ksptólbá ar:: ttot.
One or snoro aíldsíiooíd antigén*: t»ay :-'m. srfdiífeo. &amp;m® t««« iSN«:..«o^>fex»· -Λρί staff «5 psssiferdfef te diphthem sóstóid fi», tetanus tötóá-fí)* eoasé itmaííalar aiti|em «tó lstef«xifies* ttóa tPTxd), isfesssessfoíss hesmgglsiinín (1 H ferfedfe φ Mit antigén) aná *^Mim>®em •(ftmhtínO of mit. *a«n bar* s .«tat, leetóÍRg;%:« p.assvui.jrfy aásssatagoíías ssnhodisseoi D* -)¾ pfxd sad VfBÁ tustigenis rosy 1« addod 10 orá^::ts-.femHfe««titJ5itex< 1 he additional ^m^mm^-bsmiSMá iwmémi-w%y&amp; ss^méU%Mbmíng öté htptóti ti isisen aasigvss preadsorbed ti) eisher onso the totói 8m<aost of AÍOOH that needs to be present so ihs ymdm cotnpOMtioa; (ti) or· -otó ·«,parisa)s8ss«n«8|·.-:s«^^|»!»»If-: tóid ίο M rtmh $m tónl. amottni, hifensasstely. tik- additional astslgvs» may he adsorbed separately, mit onto a parttal atntnsnt ed AiOÜH jnsl d-.v she BBs.Ag. A mixed adsorption- grocer may also be provides! ibr sosoe aofigens belssg advorbesj •anmrateK other.-' being #sosffecd xe^atóilly. V>v v k mi wt ukt votaodutan m *»<e o^etltró^mdlinidoibe-'áavtóto,. .-Sifted a dor site addition of vacis ssisitge)».
According so one advantageosfe etoifeénntó* gsyenoniy by w&amp;y of exssnglih the fiiisAg ss adsorfesd sepsnstdiy onto a partial amount of ASOOÍi pra^ai ;n the final composition. fit panidof fho li> astd:l' assfi^iis as« septófelíy adsssfi^ noio she gdtfAlosta! pass of dse AiOOH. The HVl arid TMA -whiacplag aoagfs snfipos ars ttes a^fed to she;:;pr«|^mUors-t^dMmhi||: she AKX>H-lvr vo»npfex. eaeh of ifiessi two ndtospistg eistfgfs ondgsos fbefstsoive'i having been iadsvakiaisy pfeadsoíhéd sthfo AiT^T ^msdty. ®d· f^f^snrafiott·» fAtOO» ' HBvAg cosnpfex and AK'tOH - D-T-Pfxd-f1)A «orstpfey) die: conthsodd ikSíASdoiorsri a psspsmdiöo eoshprisapt she Ak κ.>11 tIBvAg-l1‘^tvd HiA so tyftfeh thd asrsosgsts ot eaefsidf the ofeotestts have:: beets oktsmsolo ohdsjn mmm. ehgvesgiosgdlT' irons 5 to 17 μκ ol HBsAg .·' dose; pseferahh i ft μ.> s dossh dons 20 to 40 Lf of D / doses preferably sVoos. 2? so 55 fSr slose; esgfroty pofesssfdy 30 Lf / dose (Lf- ifndS:ofiisteegferidn) (esgross^f5¾asvjfser t^as. «he sosooso «t ft »v ^catcr doto)> ihnn 3 to '25 Lí ot T ί ptxfershív note Rs k< K- Π dicse, ensiseSy pretetnhfy Rl k-f >' dose ieo-o'-sseO n ux'thóí oat, fsv ,s'TK'»u' .ν' Γ !.;·ί.ν.'ϊ úi -.i; ο' cOvoP *o 4ó U,' dosts), írom 20 ki Rs >rg oH'HA í ek>.x\ ps'to'es'ehh 25 ng / dose, *ÍO K'< 5 <\li \5 i\M ' C t. >>5> X ' '< » V ÍV; $lfi>t<li.ng to »oe particular embodiment of fh« invossisss, folio artiigeng, Which conveotteaMy #b:$lsí 01' s«,s''tsv'tmg v!í\! too -A„: addeo k t<o e-oooon>\l ϊο aed ρ-dnoüUí.>'\ o; ths t tspes mooíh, ps\?ou5 ** pdsasrit: vaccistess, i.e, types i, 2 ot 2,«? «lse, its the iísi ^sat ti would oof he accessary to vaednaie sg&amp;htvt Ée-3 type». io introduce only she types agoinst which protection ts sought. The anwuefe ot pohovsms per dose ?ósy iu particular be betwee ^.u -»ΉΙ »V**'>t ' m' sp -o > 4b t' rcr\ \ ste..! ^ í'>i o Ot *s wtKi <' s miw between I? 85id 36 ídi, in particular >2, tor type >.
These antigens sf« not »?ce»»rity preadsorhed onto- an ahansnssm s&amp;ii hetibe being addesl to she νρρϋ&amp;$ prepát atKss. Λí. eosdissg so esn- punieutsr eosbsxlimesu. she nuohod aeeosding so the invention isti method wherein: (0 its) the TsUsÁg tssid ít*e AlOOH are brought into contact in ti)* ui veres of nssy other antigen* and:the JIBsÁg Is allowed to adssnth onto she AIOOH Tor »t ted 4 huurv, preferably «I least 12 boats, estfirofy nates e< \ eg" ^ n atyK house e-eh* nr spej station cwttsnn s»g <m Mi KB! HR Agv usrpSux; (;) ;b} .·, preparation comprising she 1. Pi'xs! and RiA antsgesis. prendsorhed onio AIOOH, soul optknusSK mkhsionol fieic&amp;ioiVn p-.-nut^s antigens. such tss periadm surd aggSHttegans, is added-to rise pa \usd ό obkooed » vndps'h 0*> phosphate ioos a»v added 6> the jnepsfasion obtained in point {ss ib) in .order to. 1 :.Í.<^Í cesíoöskrassoss is>. the vaccine <0 4Í) tnMoM; (in) polio isoUgene ore oprioeshy added to the reeperetiois obtained sss point (ii): (iv) a pteparaiiott eotitaiithit: tiie Hth onitgen is added t» the preparsdion obsained inippmt (hr or |ssi|; (vj She pH e .uipi\5ed So ?.S ,:,4.1. as:d (vi) i<5! os least ooe caiiome amino »e*d is added so as ie eompiete she prepismtloo «Mated :id ssotnt i is 5 or {vss ixddo.' she adást I»» of the ΗΑ antigen, os' 'J>i at lea>s ten- iOSecec ososou as'sd :s added So sS.o shh áassi.en J vthoie at os k ^ leoe '4 s os st aü > u t ‘ »v ttn -. \ >o htdhe'vsssote os as less! 100 osg's.
Arcerdistg so -esc psrtkoior esvhodnsseist, hie sssOisisn· esiistposhson aceordsng h> the mventsitji x a ooisgsositiois cosnpsktnp ilissAg. dsphsheria torn· I), sessssms tócsa I', the Pl>.d end HIA ohooping ennejs ,οΟί.οί.Ο5 h&amp;tsng SvCn pi .adsciS'Kd Oijso AiV'St it I 0"' t Sd' .-ns i' aO>\ OpO ssso S'- she pnhe -. ,ds :o,, O: v,' i,}, ikast''s a f ,<m>ohk <! , ' s to d >·ικ'.κν\ \ i-UV \g piwm s" h xosrp'\5t\ ' \ kv'ps noaostted on the AiOUH tor st 'east 3 «moths storing ttom tto' dote of snamtfacture <*f «he cítrajxrviissm stored nt &amp; tempst'ottne of > * ,3 \.; ttod <n) iu least h$%, 70% <HAji*fcmMy 7500 of Jits loti! smtottni of t^:^:|^ípá pSÉtht' thltti:' «urapositioo is oos adsmisiioolfist AfOOH, ifps ^öüntf^amfftg isíkiivgp sísmoveí time. 5;s addhims by vntue of'ska method necordsssg h> iho mvmiiion, «ho antigens other «hart HBsAg tvhieh shooed that it was mivimmyeos^ for thorn to be adsorbed onto aiummasn oxide hydroxide in order to be aomiomgeoia, mm tiKo kept adsorbed. lbtiss ft jg indicated, by veny of exitmpfd ihnx &amp; «ο«^Ι|Ι$η ftbdiÉ®g.fF'®^ fn^hiónhAfty sospprtsl::
IdiA f 0 to .30 pg of HBsAg /mi: preferably 20 pgdhtf;
Stom 00 to tiO fdot D'tnl, pretetithiy- from 50 u> 70 U o»iv tlhsn IBM SO Lf οΠ'/ms, preferably from 10 to 30 If óvd; from 00 to 00 na ut FHA ost; pmsersbo SO pp nth - finnt 00 u< 00 pp at f* fvd'mL mermaids 5tt pg mi, nmn 3 ut«ti ogof t'RPnti, psetesafdy 20-34 ugml; from i to .7 síig s> AR)í HHm pnAerahK I d mg of AiOOH nd. phospisao ;> '! s ,o o .oneustiudm* at 3? to o? snMoi * psetesabH from OS u> 07 nvMol 3 of phosphate sons; frosn 1 00 to i {300 pg'mi of cationic amh«> adds. prsAerabfy from 40# to 800 pgétni; and optional^ p,d {t>v!fo·; types i, 3 and 3 in hnsetlvated Aims, in n ivmxmtive amount of SO, 30 snd 04 DU/nd
As psevsoosiy üsdsaaíed, a oontpcenoon aecotding to the invention smsy also <.ompme adsition&amp;i Bonh'fdk) l erfusih' aistsgeos, such S'- pertae.ms t<d 09 kDa) o« isgghnifiogcus. tkseripssoo of the tlporv ! igm, 5.- a vchen-a at s pssm mi u-eb-mi nm.ua; ,a, \n«e U earned smt aO-a -v addition of each component 3Ak01BlS tmiovts mhn'aie pteparstihm sd n hoik t2$d 5) <« * Ikpft 3.3s 3? AiOm« pdto Hill hexnvetesst xasoCihe 5 toe pteporation is ossned not undet .-tetiie emelmon - atsd v^ith «mOimams 'Sitrae:.
A Frppsratios of líBsAg sdsnrbísd onto AiOOH :A Mn'ii>g<s55e3At5t $«st%tsiofi of &amp;iut»mom nxsde hydroode {AlOOHi gel -sold by .Bresnstag A03. «3 S g of niumissíümdi is introduced asoptscsUy mh>« SO I tanh.
A3fet ^stnejtion tfnotsgh a..o 32 rot' idtm she volume o3 RBsAg teotoreti m e'btnsn a wkentity#* of 30 ne *ot m the tbe;d viter ate ss eontsoaoissfv ndvkvstothr tajvh aiready eofitasmíjp she ARtOH t t'r ms'tort'm A it to its to* 30 m 7 3 iu««s ,0 ,,)s,hsent r, nt|V\4oso ;.o a< toobt,oa a homos mu o; s NOH-mneien B - )be§wsstftra οί 13 * 1' » IM'vO * Fi i Λ sdsörís^l »«U* »!««»»«*« gel h'i $vsr,:Ok-l, δ m; Ahfe os' aisimiíiisss* gel, diphtheria iwxokl (öt, tetsssas tossral * >). isordairihi portássá; Sftxoid ίΡΆΟΆ v v ι«» \! t*Mi' Ιϊ> ΪΧ ίϊ li S.J It! ' i í \) \ P V l'd» V ' ÜXs ''' Is A homogeneous· s«s^m!öo fjf AI0O? I gél. söi|i% brpddi #0, ht f g sr>so &amp; 3501 tank d u > '0 ini h * Be* vj η>νΊ o e* V'Kv ss< < ' m^j'Kuí 0ts\ 1 t t v *hs »gx * i)' m,t >vi ! tin k Iíü1 v ! v »' Us Sk h X H'ü » u<k 1θ!>Ιΐ! ν*\ϋ\' j 1' >;<.'íh enUftüou» !« she ttraft xs»\'»no ut hO I f (hmsí ot ntKenkfton) mi .smi 00 I *-'mi O-kc *hc hóm*. &amp;e neons >»'\λ v has Kva eb-a u*t Λ vustn'ivuon .ot ^UO |>»-«:«»L»Mtíeo.ont«,Ak>*2t* :«»«1 ife&amp;v Őse suspension οΠ'ΗΛ preadsmbed <*m> AiOOH ere siseeíssivdv .iddi*£a«9tfoú&amp; «ttferfti ksÉ* k »o)er:?o :í?hkk. PTM süni FliA .eoüppitatiohs in Ősé tip) vhpsftg:ef2f Bgmsl· $1#%, Οι* vohísfö dí :M ;s|M óípikptae hifiik· repfftM ίθί:01>0θί0δ Irtfó imlMgi/i i$ Aided sOin* (iiísdfko thtoggh s 0.32 piti ipftBx i! , í!v í \ , Π \ * kd, ". i'vosw'ri ss tód s<:>sls·' fos- at lead 14 hours at a ísm^xsíííU$re oí5 t :);>C.
Γ - Prepanstmu oí the rass-tiire ot HBsAg t 0 ♦ T * f FBA lie ^νί,Μ a so* v«s δ 0 apes»' % a a hk\ »< ptm t s ‘ > he vSASsft.><.ns>KaiKd >>s s.s>sm b 1 h s \t te is k0 to -sí! a ' χ{ δ ΐ} a eg- \ v s m spension, !he volume of $<K> mM phosphate bs;!T»t seipilreii ΐ·.> obtahs a phftspj'i;sie; sfts> eoiU^!!stebi5h :0f 4fl :S3klO:l3l in the Oha! ftomptsitson ;s Slsets adtlftti after ftjfrftiiosx shsoiish a 0.0.2 ura fsbes·. 13 - S&amp;tso'fttiöu ot the eleetrostelk sites ut she attsmssutsis gel ItOsAg * l> * ? -s FIs si e I it Λ .eemjrée* wttfe a solution ofoutino acids A solution stfissTSisso adds eontasmng i 2 essesstisS sussisxo aeOSs. having she tollowing cftss^ieslit^hx^F^ft^®^·· - Argmsrse hyvIroehios'sOe .,.0 1 g/i, i.ft; ).75 g?iftíhígkifte • C>SSÍtK: ......);2 g/i - Hbikke ..,,s,,Mm, 0A g;i
·>:. |:|ti|ftíip|áft' , - < : ν::ϊΐ:':>Χ'ΐί:: 2 6 gO
- j.endue..................... 2,6ψ I - bysise .hydrochlwkie.. 3.65 go, he. 25) I. g,d of lyske - Methionine............ 0.75 p/l - I'heuMvikonne . .. 1..65 g-i -%-mötsiöe.,;·..;.............. 2.4 g/i - Trypínfskan ·.< ·,:, vV.,.,. y.,,,.,. 0.4 gd ·· lyraxine ! Jgd :-- ¥fc,,.....,,,lip
Thai k k< ss»\ 3 5 v* g.d d^atnlno·a«"y&amp; toe.U«dWfc 5,44 g··i os'utionk amino *ckh <H«v Arg - Lyx}.
-On* ' S v *t x H> i ^ *» S ,!<» ^n>< Kiih 0 , ‘ ft'K with stimog iw Id be 11¾ amino MÜÜ sAifenvilBi^^iiKrosJgk a 8.22 pm filler w cotusmtousty tokkal k> the mixture obhihsed hffe m m··k?: PbfA 3:gooeegkatkoyof -|f|-pgtitI of estlnpip amino aeida In the 8M;t^mpsíjkm, K -- pH Adjissfsrtent S x rU or ms suspenxtenropimtted *« posm » J "U'i I ' -Ogu' u\iiv * * ‘sodium hvdroskSeni2.5 N. k -- Addition of the pofin atifigopi -&amp;:.preparation eopigpuog ppltovitm xerotypes i. - and > ut inactivated form «.Mahoney* I and Saohett xti-gpis, rssspeetsveiyl iMiered through a 0-24 pm filter. is shea introduced into th« Sank comamutg the suspension obtained in E.
C - Addition of PRF T
An smermads&amp;te «.ohmon -d' ERE- Γ is tirsi of ad prepared in ibe foHrwmg wav; Trlx-mcro-sc bush-.-:. fdtervd ^forehand through :s <U2 pm filter. is added to a preparaiku? ofPRJM' filtered through a 0.22 pn? fdlsr. so as :iseorumsitse an mte« mediate mi More. S'fds i* infiod'iMNi weptsoaUv m«o ski. 'mentre otmm-'\i in S', H - hinat adjwMtmmtpteie \lt! VI I «<, < (. d |ac i J\|V is OS WO vl i «< « <>' fOnlpt. iifp e. ui OSiM.A Ά * i< Vida, ι <i in seuee dii' t&amp;tuet vySame ni i'd s s«. added. I he». » sexessan, Use pli «r «ρν m-xiure is adjusted ín pH 7.1 j. is.: hy adding a nreíikered 2.5 id sodium hydroxide or kt% acetu: amd solution. T he mixtme A stored id ? ;- ;V <; inén d'xt< ibn'ed smo i»yr>oges or honk;. m a p»op<>i Oon nf Ú 5 od do -'
Ode: d.5 nd dose dnn. eogiaisk kOd ggof A= :ih i 0 ug of Η'ϋχΛκ, no ipsa than Μ Η i of D, m k*s* than 40 M.f of Ti lS gg of fs, 25 gg of i-HA, between >8 mtd 43 Dii {D anttgeo o«hs) of poito type I, between 5 anri 0 i >s s of poiks tyf-e 2, between i? and id DU of polio type 3, VI ug of VfiP (in the fortn of i'RF- f). phosphate ions a- a ekhkenSraiKni of 40 MMnkl Tris-iaetoi.e hnSor at a uoneemnssion of 2.5 roMol/l of fris anef or 2 t :?.55W-of· sucrose, arid nko aao ug oi i.atn>nie ..orbno η-,'χΐχ sd us -- Arg -· 1 .y-.,,-. klithkaldridl;:
Ilte vaccine contpnssthm ptapami oceenitog: i&amp;ihvmm%$k above w^tósá^-a^llateaí *rlah eompreddfea hexctvaient vnccin© aiteady pteaent oo Ahashttckeí, vttddrett against the same diseases as tbc y atomé ptepoted aeeotsJmg ío &amp;»st»ve«t3ao. whooping sxmgix politx Hih ntfeetkmc a«d hepotttw B^ bsx wblebíbssib líssífeölar the drawbackthst o pstst sí $ is iyophiiized and therefore nxtsxstes on operáltat) to take sgs Ahes Ippbsbsibs |5s’i<'!' to the sdsnAAtsStsa sproeedtae. tSoHhgdfr t't««Kv' «rxn. tk ' vu e* ofv^* « x - ^npoeotottv were· ottoWibrdííf^.tfi s wssethesohosos; cwsipSfsthg lidíWhs ddtöhitsisíed 0É3!$ attá b sooaths. Thei .lápod. vaobioe prepared s8«<^éis§.-M-:iií8:5s»attioá,:ot· ihe· invention proves* fo be vers welt federated. ami as o«t»»»ö|ostfeas the vsaésbs prsssbtíssss thomorkeo
hXi^RlMENI Ab DATA
Fereeotage astsssrptiOS of íJB* Ag/amoxoxt of oosmhxorbod FÜí^T
Thíps hawhosóf ihat bxdk product (Pb V3$*4l~12> ^tWfe:S^^oh^áiS^iÍJ«teáint#tófe::|I:11^34I)···”' alf the hsabhes haváig 'bge».:ebtaxsed sasordbxgm d)s easn»|ile provided - were stored at : 5*C and «?«%·:·>*;! at wsricssx* sím®s sverw psíMfMFF -and 22 motets*, the^stseo^tMia^ioh· of HBsÁ;gaís#:f:hs ooxsoíh^
The percentage adsotptkm of the VIBvAg *as dstomdaedpas- was pstídbasly Mieat<?át ttom the tótat liBsAg; extent ana the noxxadsorhed BBsAg mwmi tbs mtb-»s%g:s:sas^feh Π IS A method no-cording to tlx· shies defined by the laioipto-ifiraeia^sta^itvb Bt#%* tho f !B«% was captured h> an asht-MBsAg prim s v tao ><. s o * dthex, of h>M t> f> > sw b of « *»h west pitxe t ne UBc \>>. this hwiiii was Mated: Aftthüáa anti-HStóg 'sm^k^monoeiöt^a^ii^yj o^ip:'ií^· whísh wtor hsssh' detected hy means of-tsg^őaidasss«ö^fed atü||P :p^eS*rt8Í: :a»Ülitoáy< Á: lahwapphte. :s8hs?tste tor tpsroxkhisib í«,U:o»»<".rt>1benaiöine tTMÖ), sx-t veá-as· «-dewloplog agmt>: Pheo It was aháetb s ooIöe· dé¥etope4 tho intensity of wttteh was p^Htríional to the amotim of HBsA| oaptoraslia ithe wolh 1:'he: sesoka: wore; 5 !ÍW( >d> the M! twuu W Vfi\'S XX ÍO^í ü!KO \ ^ to order ίο dcteíiflioe the percentage ad-ioqdiotí oí hie Uíb;Ag. she vnacíse was eohncleh to <í-'n-;rifngst>oa ,^gpO g; 5 mf\; 20VCX which made il pocink ;<ϊ íoceoer the supernatant contain mg ttse nooads-wbed HBsAg. S be saovgias oisopemahmts to he tested were mhaed so t i tS.A hotter eosoprssosg a dea^rpttoo hssOer, in 2-sbld sedal oiithion» in a «attge incHtdext. for «sample, Ixdweest Β40ΰ οίκ1 tíb> ht>d, jt O SX SXi V ΐ Ú f * iti h ¥> * >1 s I ^ \ Ί ^ e't onv'gft ts s'i 1 ! ! t i dí#lá;sátM IbliÉsat»^ hetwoeis l/ü.gnd
;A ih-wels sdsie coated whh the pitmttsry nscote-'toosti tssitshn-.ty was mcotsated hw \2 h as AC and then washed svith is PBVTween ah cotsososx Use ctihshcasa >s' she syp^nafasxts, <>t stse total varessw and oftlte sssassdssoj range wese dsso'sdmed inio the weha The sr-xasthwy asohx?dy woe then added anditte developing oos estrried oos with :t!?- xu s t ^ i ο,! v ϊ |x d >s,v< 1 tresnsO c 1 eoesAw) «V v sv x·- t>s xsd* < S H€t itefte was 3Ö wíh ?lí« #!§*
Iwee» 2ö sobdoo. A IMró '(áieített baí&amp;f} .3» .mtó«á. te·: Λ» ρΛΛ: weUi. «hkI oí^ws^t. ito is&amp;me PÉmaxav The pkse wasMáaí 00 4li «S $M 88¾..
The sammoR of ííiosadsoAed RRIM' wss svalosssefe fey HPÁBC-TAD (high pmfmmm®· mim spfesop «shmsnaíöifsphiyio:pdskíl delsefeoo} I» iho;Édlö»lo| ^sp á siásdassl raep :öfím&amp;rsa«e i BE.P*T of ISA fe> ÍZS.^míwmfmt of#U fnspnsá 1¾ snipes to Be fessed· sssi sise lhe-stasiiaoiiraoge ssmpip smo eeooifeípd as SOfKí g for Λ min as smfe-em :iap^ÉBsl: Tho soprossMix :wer&amp; eolhssfed ásd diós hy&amp;tiágz®$:, wdSi:3: ,h$ N NaO h»1uUo« conMining ghjeosasíios'· S->phosphaSe as mlsnsd ss&amp;odarö. A felsők p<R% M8C| tM ki -M&amp;Qlí -r intvrml α&amp;βώαά) λκν Silded.
The eferomaiogt&amp;phy sv&amp;s csnied mt wdh a moldle phsss composed oí 3 5 mM NnOI I and I i4 öíM öl sodmm acs-ate, i'ojéxaed inio the eofesmn as a nde cd I 2 sol/oss. í^iMasÉlph# WM»rii£iq0H${ (Boriké ««.* of the PRP peak * sütik* »tm f f: |PIP cookíksiRidl i-hw· wfeki !ía;í ís she slope and "b" i% the hpjpgf bps llhs. fesi»«í.
Üss<%sörfstk?osteef btsbíhthe ^iBáAgeös'síamöílp hitéé hlfehéTőfuhat bhtbpaehaef (FÖhiS-tfccse bMéis^-BiÉBbyíéggntíí hohley ζβ 44-45-4¾¾ ef u;ik|U|4 0bp4ibtiös eeippibeh4441)4: s$$M miigm&amp;fak ofammém^ráfag fa a jihélit heSöathtá 4 pptri áip| BSsfgftip BíBImít !Ms that destahheá itt the esaiepie Φί>$% «&amp;$ abohesiesi This pte|5afh|lás eMbihéiT ifi 0.5: tál: iÖ:kj| öflIlsAg, 3Ö Lf öttHi SÜ Lf öf 44, 31 μρ öf Bt, 2Sp|eof FÍ4A, 4h DO fif fgtttávihfis typé l, |: t)Ü et poiiiJVii'uS Cvgá 2, 32 011 ní'pohövtnss type 3, 15 pg »C;PBh0o the ibris sí FhfF-T), Ö..fi sfig öf A!, fihöáfiháíe Ihat át a eöséesttfMsás öíbá ntMoMitsafitonafe ions et a sííataetítítóeo of 30 iskfót/i, Tab-suetese bhfíht át a éefiefeéfiMkíh éf TSpMoi/l with tespeet to Tab: and 2454% with respeot to etweese, ásít 14 fig. ítf eatíösb gfiühfi sekis (hEs: --- Ábp - Bys) oHghsaítog trónt the Mi 44 m«4iam.^íio"val808«)» gB 4.4 - 4,4 , lltstessiB obtained were the íiEkswsng:
The aíráemss ot noondborbed EÉF-4' íseasateá over the saste peaksg showed that: ihere wfis khíe: vá$áik>fi eosspared wish Esne tg ;sk! were therefore saEstaeiery,:. jHówéyers these re&amp;uifö, show :ti?$h is ihb eáhe, Mfish

Claims (2)

  1. does ns>t corfVstptvid te a ínefnühniOü sA'ismed hy vessz rd a maisod zs ixnvhng to the snveníjsHo tns- uepsishg B SzSidttev KitdgCSX did Oot r'ertuiiü iidssüsod Ott thst .Steossem OXsie OS sls'Ostsie. Experimental tinta relating to the c;ma«h: amino tieids Λ cs'-n-posilion according to the invention resokitig directly írom die expó'. intendő ptotocol cacti esi oat in ate ex ample provided arid a composition obtained by vn'toe. of a ptorovsn tnodiited in thai a composition csmtalnisg only the three eaitotbe amino acids (Arg · t.ys ·- HH) bad been *Bbtfi!t*f<l for the composition of the id essen! tat atom» as ids vvete esnopartrei o itb teg&amp;td to she nomtdvortsco amoom sit t hi - s at the cad, oio ctols-re m e h* the amount of oonadsorhed PkP-i oso observed, thereby soroséig that only the eltörne amirv acids are important. i. i.djhm folyékony oUbanysigdtomfeírűelö eiMiitusáta, amely tartalmaz legalább ,d»mhmmi td-hkii'O'sidse kAiOOft';. vs heistOftsz fl Svl\, ss etCigCist $He,4p\ cv >! s » < » . s* χίίι'Ί aiders, at s v hotdnmk * pd-v hot ,η-h κ<ρ ndst-s pofesaeksBttiiiS till, alsói a..:h«|pfe« Bi fels^at aiiigdh AfCXdlbh adsmdioafva yah, rotg a Msb antigén net» asizeieva VaOt:: ahol - a hepbife B iisgihi tat igára AKX>Brs suBzxirbeáijuK, Hy módon AiOOSbHBsA|ykompiexet kapunk, a AtiXdnilUAg'B-'iorb'v legalább tt»t> no; : ksma'aou >0m Uinmos •m-ms-as s-s l'' mMott koncemskiciójó idsztitkm jelenlétében ósszsásívs-sji.ik a Hit! antigénnel. 3, Á® li igénypont szerinti eijaraa ah»! a HBsAg antigén AiOOkhiznszpenzió ás BBs.-Up'sUi.szpsmzio ispiMhb 4 drln kcreszitii történd kövemével s;g» teaekeverésévd vsa as tdundmomra sdszorbcátvs. .5, A?, i ias-isspotii szérián eljárta, shot a HBsAg antigén AiOOB-'-eosepeneso ás lIBsAg^wisrpeozio : e i i ·.!>" | '· , g g,^s s'»te· o's t I' <do sWsrae t issna* diám mii d » hs\tB h. Az i igénypont szérián epriig ahol a IIBsAg antigen AiGOJi-s/nsspenrid ás 11 Λ-srersí:p*íieit> 'lögáiúhh 30· 34 Órást keresztül tdrtenh ke veresd ve·! vald ósszeketetésávei van u *mmt«H?rora ad»zorbeálvü. n ,\f igénypontok. bármelyike szert ri ή eijarás, s23.nl jeliemmé, hogy a kát ionos enenosav a Mib ghtigennel t«tUNU> íkvvs-ks venB ehm van ne AlOöH/HBsAg· komplexhez adva. n az i vágj a 3. igénypont szerinti eij.tr.B, azstüt loilemezveg .bstgy a katiöstos aatimsjav az. AiO= >H ; n. \ -\*>" 'kwJ '0 i\s- SüvStvis t ΐ b stg^nk' A4 7. \s eie/<' u'án'Penis'v sarí!>...'hike ízért Ό en-ees, gzzat jelhatozve, mgv <* k^zlht-uo e Bt"· üntigébhel történd ó^zaktrwrás elsMt van »z AIÖÖH/HBsAg-komplexhez asivst. 8·. A;í döA> igénypontok bármely ik« ta»«nti djára*·, »tml jribmetM* hegy az AiOOH/DBsAg-kunmlexeí tótóltoéöy ι»Η-> * Hife tmmb asvtkovews dbu \1*0,I énekre san beáiigYÖ. %s i „e ' o\ ήϊ i c· v* **«0! MUme*'·*· »> o ios>. \ ' I <. < \ 'As - tegdább égy* dBMns-, mmUM-t pdtkfc· &amp; si^máfköiH^ésAMA»#» kftcBi vátesaiotf aseiseml és Ms!tv&amp;|AnK>Kkkhkk<;xkk>5 tartalmazó kéaxítmány előállítása, &amp;> az AIO0H/HBsAg-*ompl«s bssaekeMíféss· a kí*xttmén»yek a ΠΒ> aitilgéonel történd összekeverés dóti. Λ U* ! ,íhrΆ --,¾ί ίϋ ,Sí - ,η üü'fisl idUste^e leg' * kníe\ \mv! > j kevrtoa'ro doAs''kíní !' HÍ. π V π<. ,'kOgn! . iV-Art kín Cvó by <Ti<.hvOy: UbUViÍíiU0V^N^'h«1nkV.vkx.tUa.;^)\'SÍ>l«E:,í és keveréssnl mindegyiksoJigémlKi:í,z.á3eés közbe. U. Ac I. igénypont sjwrinti-eljfcfe, asual.j«limi'*ve, hogy tartalmazza a következőket: - 3 BlksAgmik az AÍÜOlt «senny igenek egy sészére történő aősaorfeeáiási*· ««ely a γέρο ké-Aoodíyben sdemévö ísíísí, AKKbli egyb&amp;nnsdn. dKB oráe ketesztök Ily niődon ΛΚΧ.Η0Ή B.;Ag'komplex • pAtim/amo**» a következők egymást kővető adtoArbeáláaa egy további AkXSR'mtsmyiaégre:' difebheovm (Dk Eídonisnobo i'Ti, Bi'-rJstetiü í'wrtif&amp;'ii*· tisztított tözinja íPT-Híi); amely R5aga.:p?eads;sörbeáiv&amp;: AiÜOB-m, és B&amp;-<lcttiiie fiUna'nitwus hemagglutinin (FHA), amely maga pt^tóasbifeálva vm AvV1! i iO i .. O be '. < J Ά^! iiií .V XkMjB. IP Ά, XO V Λ w epéx A - tbíszfStionok ho/z&amp;aláui olyan e»«fty>*égb<m, amely tehetővé teui a végső késM$»48fl^8'"4ö. ffiMiiM koncemrtk;«dérévé;, - tvgaiabb eg) k«t Ionos amesosav höz.?áatteaa olyan mennyiségben; amely lehetővé issd a· végső késíiliíH s'sben legalább JÖÖ mgö koncemraciö «térését*. - a el í bed leess d Idi,1 ertbkn, - ^olkesfíligének hozzáadása maktsváfi íimtáptan, * ailisb .set igén hozzáadása, - a pH bed ihass 7,1 dl,; értékre. < ss v>rtk>srtO·' lí. -(crtos lás' b^suaiom. \ s «. ain^kbi ti! A?, eiöso igéoypoorek bénoebAp szirtijei eljátáj.. a.sral jsliesa'sve. Ia>gy legalább .7>0 I isbónovog-ks-'s'inen> ke··.Ad rgen mertékoen B, OH»km).ag-késziiméjsy, «πκΊ> az eíbrti igenyponOik !>ám*rty»ke szermb dekami vas» eiőáiHÜW^.'is. u>iJMi/.rt b'gsBrtb s begs,íi.sz J5 ebem: sebvéni v}ütsAe) λ a sbb aert^ot aossiyej Jesanjjvriehéijébez 'köJsjegáis poilrlbo/énbeoe fon/rás alkot. bl Az vlo/b igessypo’d sreroiti olKaevag készeotóex azzal p-ikesezvé, bpgy: tsrlsiéísa:: tlíftemn. ítemM.Sk>5 pobe- 4§ skMekkdhbgns-sfitjgéol h. 15. A 13. vsg> bi igiíeypooí <®amu oitóanyag-kásalsmény. aszol jellemmé bogy mrf&amp;imam· bpláldk - a heoatisisz. Is ieiszml síglgéek HbsAg-t. - a diíiériaaebgdi} tiiftéíusíosle (i.í.s femeekhaiy a íekeoisz.oaigéíst Ka&amp;oussloxle (Ti :l>te4jábaeS; ,s ti>OP 0**8*1> fíksSXU'aíAítíS Μ軣*Σ*«»»ν pN$) ÍÖSTRÍp' l»5Si .:f»jrm#N«k ~ si polk>&amp;f5(sg£oek«( 1, 2 <5« 5 íipusl»H3 vá i;ms ok in ski ;vál( v i su-s RsrmpisHi. ' o \ U W5 n\ ^ho«r>v((gU't,'!i(5Ci"s «*osl itfkmxxs* 8*>*(v kiosdrs VisS^h - 10--3(5 Mg H.BsAg-t KiilHHfcrrasakeak - 40-8(51. f B?i piOf teöí&amp;áOk - ;0-:K>i.r r-í!«jliülí«et5ké(ik - 40-60 og FHA-t mimiltereokííO, - 40-"í*FI ví~t •lüSOOx-ftnkí'ni, -:--60 y« OROo tmihh&amp;renfccnk PRO-r-kkftjagsUBR - *ng Λ MOH - msOsfsMa ski's - .53-45 reMökml fos&amp;Oiou!. - H)0-:0UO sr>g,0 kaík-ixo aHo«öS3v<j(. - s--s:s. .?-«>. «s. ,5-uá Opusa poSiovOast is',<fkssv;\U k>wuáb&amp;!k S’Skáro ffi). .16 és 04 DEúnf íMOSfíSsé^^- 3 7. A 18. igén) ps.>nl ssermlt olídmy»^·ke><0««én>, ra*»I hogy l&amp;ípmuMopIPte - 0(5 Mgknl BfesAg-k - -(5-70 1 1 i(0 D-í, MMOU/m; r-k - SO MgOssi ΓΉΑ-4 - 40 Mg/íík 0 lAO-f 0 >' j ís s5f M > ingák? > t sPtkiik í ' - 5.5 >s;g/s'íi5 AK.K 01-5. - '13.4;: mMoik íbszfáliosk - 400-808 msy'l kutlmsos &amp;iyeks>say.4, - j-si..
  2. 2-es és 3-55.S lípusú poHovImt 5rsí^kliváli R(rmá4>«í>? gstsdte:1 lS ésE>333ssΪ
HUE13704171A 2012-01-17 2013-01-17 Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására HUE032539T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250464A FR2985663B1 (fr) 2012-01-17 2012-01-17 Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium

Publications (1)

Publication Number Publication Date
HUE032539T2 true HUE032539T2 (hu) 2017-10-30

Family

ID=47714410

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13704171A HUE032539T2 (hu) 2012-01-17 2013-01-17 Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására

Country Status (34)

Country Link
US (1) US9358294B2 (hu)
EP (1) EP2804628B1 (hu)
JP (2) JP6199310B2 (hu)
KR (1) KR102019848B1 (hu)
CN (1) CN104039348B (hu)
AP (1) AP2014007848A0 (hu)
AR (1) AR089737A1 (hu)
AU (1) AU2013210927B2 (hu)
BR (1) BR112014017416B1 (hu)
CA (1) CA2861304C (hu)
CR (1) CR20140356A (hu)
CY (1) CY1119206T1 (hu)
DK (1) DK2804628T3 (hu)
EA (1) EA026058B1 (hu)
ES (1) ES2625011T3 (hu)
FR (1) FR2985663B1 (hu)
GE (1) GEP201706642B (hu)
GT (1) GT201400120A (hu)
HK (1) HK1204293A1 (hu)
HR (1) HRP20170692T1 (hu)
HU (1) HUE032539T2 (hu)
IL (1) IL233643A (hu)
LT (1) LT2804628T (hu)
MX (1) MX349411B (hu)
NZ (1) NZ627345A (hu)
PE (1) PE20141515A1 (hu)
PH (1) PH12014501546A1 (hu)
PL (1) PL2804628T3 (hu)
PT (1) PT2804628T (hu)
RS (1) RS55962B1 (hu)
SI (1) SI2804628T1 (hu)
UA (1) UA113000C2 (hu)
WO (1) WO2013107988A1 (hu)
ZA (1) ZA201405431B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
KR20230173114A (ko) 2021-04-20 2023-12-26 케이엠 바이올로직스 가부시키가이샤 6종 혼합 액상 백신 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283910B6 (cs) * 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1414433B1 (en) 2001-08-07 2006-04-12 Laboratoires SMB SA Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Also Published As

Publication number Publication date
SI2804628T1 (sl) 2017-06-30
CN104039348A (zh) 2014-09-10
ZA201405431B (en) 2015-12-23
US20140370049A1 (en) 2014-12-18
AU2013210927A1 (en) 2014-08-28
EP2804628A1 (fr) 2014-11-26
FR2985663B1 (fr) 2015-03-27
CR20140356A (es) 2014-08-28
UA113000C2 (uk) 2016-11-25
CA2861304A1 (fr) 2013-07-25
DK2804628T3 (en) 2017-05-22
AR089737A1 (es) 2014-09-10
PL2804628T3 (pl) 2017-08-31
JP6356886B2 (ja) 2018-07-11
AP2014007848A0 (en) 2014-08-31
MX349411B (es) 2017-07-27
ES2625011T3 (es) 2017-07-18
BR112014017416A8 (pt) 2017-07-04
KR20140119109A (ko) 2014-10-08
PH12014501546B1 (en) 2014-10-08
CY1119206T1 (el) 2018-02-14
HRP20170692T1 (hr) 2017-07-14
CN104039348B (zh) 2016-05-11
GEP201706642B (en) 2017-03-27
JP2017203043A (ja) 2017-11-16
IL233643A0 (en) 2014-08-31
US9358294B2 (en) 2016-06-07
AU2013210927B2 (en) 2017-02-23
PE20141515A1 (es) 2014-11-04
WO2013107988A1 (fr) 2013-07-25
NZ627345A (en) 2016-07-29
FR2985663A1 (fr) 2013-07-19
CA2861304C (fr) 2021-05-25
GT201400120A (es) 2015-09-17
EA201491387A1 (ru) 2014-12-30
JP6199310B2 (ja) 2017-09-20
IL233643A (en) 2017-04-30
KR102019848B1 (ko) 2019-09-09
MX2014007850A (es) 2014-08-21
LT2804628T (lt) 2017-05-25
EP2804628B1 (fr) 2017-03-01
PH12014501546A1 (en) 2014-10-08
PT2804628T (pt) 2017-04-21
HK1204293A1 (en) 2015-11-13
EA026058B1 (ru) 2017-02-28
BR112014017416B1 (pt) 2022-08-16
BR112014017416A2 (pt) 2021-05-25
RS55962B1 (sr) 2017-09-29
JP2015504085A (ja) 2015-02-05

Similar Documents

Publication Publication Date Title
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
HUE025694T2 (hu) Fokozott stabilitású folyékony fenilefrin készítmények
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
HUE032539T2 (hu) Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására
WO2005035514A3 (en) Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
UA91815C2 (ru) Выделенное антитело, которое специфически связывает gdf-8, и его применение
NO20082530L (no) Imidazopyraziner som proteinkinaseinhibitorer
WO2005021022A3 (en) Stable formulations of peptides
WO2006136162A3 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
MX2017010945A (es) Preparacion solida.
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
WO2006066914A3 (en) Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
WO2006014962A3 (en) Liquid stick antiperspirant
US9078824B2 (en) Composition and method of stabilized sensitive ingredient
WO2005115414A3 (en) Orally-administrable compositions comprising stable amorphous calcium carbonate
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
CA3156494A1 (en) POLYOL RESIN BLEND FOR USE IN THE PRODUCTION OF STABLE POLYOL COMPONENTS
MX2007013327A (es) Formulaciones de liberacion prolongada.
WO2009080764A3 (en) Oral or nasal administration of compounds comprising amino acid sequences
WO2008099835A1 (ja) Peg充填硬質カプセル剤のバンドシール
AU2003273473A1 (en) Novel substituted pyrazolo(1,5 less thanigreater thanaless than/igreater than)-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same
MXPA05010613A (es) Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo.
NZ741552A (en) Compositions and methods for treatment of homocystinuria